La catena delle opzioni mostra i dati chiave delle opzioni azionarie di iCoreConnect a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per iCoreConnect..

iCoreConnect (OTC:ICCT) Azioni, Catena delle Opzioni

iCoreConnect

iCoreConnect Inc develops and markets secure cloud-based HIPAA compliant software services focused on compliance, workflow/productivity, and electronic health records systems. Its core services technology can be adopted to other vertical markets that require a high degree of secure data communication, such as the legal, financial, and education fields. It markets secure HIPAA compliant cloud-based software as a service (SaaS) offering under the names of iCoreExchange, iCoreCodeGenius, iCoreSecure, iCoreMD, iCoreDental, iCoreMobile, iCoreHuddle, iCoreRx, iCorePDMP, iCoreEPCS, and iCorePay. The company's software is sold under annual recurring revenue subscriptions. The company has a single reporting segment for reporting purposes focused on the North American market.

iCoreConnect Inc

<a href="https://www.globenewswire.com/Tracker?data=t6BzLIYkM2Titjo2engsbYdYzVAKdATUpngXwVnOZLIFJeWOfs8JrzmA569pg5PP_wzcfVu2vxAkFgwTviT40sMP1XwBJn9-iup44hY2Ll8=">Myriad Genetics, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, demonstrating successful pan-cancer implementation of Myriad's ultra-sensitive Precise&#x2122; MRD Test to detect and monitor ctDNA in patients.
The interim results – first shared at the <a href="https://www.globenewswire.com/Tracker?data=BdItqSDA6Al6o-I38SIC8HVerhVbF4nmX3ccqI_QUByE92yXbvem_fZDt7OQiI8cB2NKQK4abOO6M6jL-D0tMte8h9L5gZyDFjQTEqQDUNNJPBB4ksABOeMgezfAqA3z09nF2QurM9LI5SGkqo5aWA==">2025 ASCO Annual Meeting</a> by Tadayoshi Hashimoto, MD, PhD of the NCCHE – achieved 100% baseline detection of ctDNA across tumor types, including those traditionally challenging to assess because of low levels of ctDNA in blood. Key findings include:
<ul>
<li>Personalized whole-genome sequencing (WGS) panels utilizing up to 1,000 somatic variants were successfully created via Precise MRD for 97.3% of patients tested.</li>
<li>Precise MRD detected tumor fractions as low as 0.0001% (1 part per million) and showed a clinically meaningful lead time in detecting recurrence compared to imaging.</li>
<li>Clearance of ctDNA during neoadjuvant chemotherapy, as shown by Precise MRD, predicted pathological complete response. &nbsp;</li>
</ul>
"Previous studies have shown that ctDNA-based MRD detection significantly correlates with recurrence risk and predicts benefit of adjuvant chemotherapy in certain cancers," said Takayuki Yoshino, MD, PhD of the NCCHE and principal investigator for the MONSTAR-SCREEN-3 study. "However, first-generation MRD assays appear to have limited sensitivity in low ctDNA-shedding tumors. For our pan-cancer study, we selected Precise MRD because of its enhanced sensitivity across diverse tumor types."
"Our results showed that among samples that were ctDNA-positive at the one-month post-surgery timepoint, 60% had ctDNA levels in the ultra-sensitive range that may not have been reported as positive by first generation MRD tests," said Dr. Hashimoto. "In addition, these patients had significantly worse disease-free survival compared to those that were ctDNA-negative, demonstrating the importance of ultra-sensitive ctDNA detection."
"The initial results from the study highlight the tremendous potential for utilizing Precise MRD across cancer types to enhance personalized treatment and therapeutic strategies for patients," said Dale Muzzey, PhD, chief scientific officer, Myriad Genetics. "Precise MRD is informed by WGS, enabling the tracking of thousands of tumor-specific sites, far more than what is possible with first-generation MRD tests. Tracking so many variants yields exceptional sensitivity even in cancers with low shedding tumors such as breast and renal. A key benefit of our ultrasensitive assay is confidence in ctDNA results, as shown by the finding that the ctDNA status after neoadjuvant treatment was strongly associated with pathological response."

News

MYGN

Myriad Genetics Announces MONSTAR-SCREEN 3 Data, Advancing Pan-Cancer MRD Testing

<ul>
<li>Authorized expanded access for ANKTIVA to treat lymphopenia, a life-threatening immune deficiency induced by chemotherapy, radiotherapy, and immunotherapy with depletion of natural killer (NK) and CD4+ CD8+ T cells (lymphocytes)</li>
<li>Expanded Access includes all patients with solid tumors who have failed first-line treatment on chemotherapy, radiotherapy or immunotherapy and exhibit low Absolute Lymphocyte Counts (ALC &lt;1,000/μL)
<ul>
<li>Presentation at ASCO Annual Meeting 2025 of lymphopenia treatment in patients with 3rd to 6th line metastatic pancreatic cancer significantly prolongs overall survival</li>
</ul>
</li>
</ul>

Biotech

General

IBRX

ImmunityBio Receives FDA Expanded Access Authorization For Treatment Of Lymphopenia With ANKTIVA In Patients With Solid Tumors

Board Initiates CEO Search Process
Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed
Company Reaffirms Full Year 2025 Outlook
LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors.
The Nature's Sunshine Board has initiated a comprehensive search process, with the assistance of a nationally recognized executive search firm, to identify the Company's next President and Chief Executive Officer.

Guidance

Management

NATR

Nature's Sunshine Products Announces CEO Terrence Moorehead To Step Down Upon Successor Appointment, Board Launches Executive Search Process While Reaffirming Full Year 2025 Outlook

Stock Split

CLRO

ClearOne Authorizes 1-fFr-15 Reverse Stock Split

- Expert Insights on Clinical Relevance and Scientific Rationale - The replay of the event is available on the Investor Relations section of the Actuate website
CHICAGO and FORT WORTH, Texas, June 02, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced key takeaways from its <a href="https://www.globenewswire.com/Tracker?data=ny_7s0D-DqkX-BPpPbP_wQtFovQZxuvRSw4gk6tVSoZGjR14bMEO2op3qnVein761Xie2vWUKkbXa0LDrdeZEVTJl4Aw6C1DeRqFFuuqeg1BPOdvquOX2UW3UpV2FF0pjjU7STsQjumtaJ5ZutZM1w==">Key Opinion Leader (KOL) event</a> held on May 31, 2025 discussing the positive topline results from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
The study met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival (mOS) of 10.1 months compared to 7.2 months (p = 0.01), with a 37% reduction in the risk of death (HR = 0.63). The elraglusib/GnP arm also doubled the 12-month survival rate in 44.1% of patients compared to GnP alone (22.3%), with a favorable safety profile.
The KOL event followed the presentation of topline trial data during an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting. The event featured a fireside discussion with leading mPDAC clinicians, all with direct participation in the elraglusib clinical trial program: Colin Weekes, MD, PhD, Massachusetts General Hospital; Devalingam Mahalingam, MD, Northwestern University Feinberg School of Medicine; Rachna Shroff, MD, MS, FASCO, University of Arizona Cancer Center; Tanios Bekaii-Saab, MD, FACP, Mayo Clinic College of Medicine and Science.
The panelists highlighted the implications of the Phase 2 Actuate 1801 Part 3B results in the broader context of the unmet need in mPDAC, the unique immune-modulating mechanism of elraglusib, and its potential to reshape the treatment landscape, as follows.

ACTU

Actuate Therapeutics Highlights Insights On Phase 2 Trial Results Showing Clinically Meaningful Survival Benefit And Favorable Safety Of Elraglusib Combined With Gemcitabine/Nab-Paclitaxel In Untreated Metastatic Pancreatic Cancer At KOL Event

Mizuho analyst Maheep Mandloi maintains Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) with a Outperform and raises the price target from $6 to $7.

Price Target

Analyst Ratings

SHLS

Mizuho Maintains Outperform on Shoals Technologies Gr, Raises Price Target to $7

The new task order is the first to be fulfilled under the $450 million Production-Other Transaction Agreement recently awarded to C3 AI.

Contracts

C3 AI Wins $13M Order To Expand Predictive Maintenance Program Across U.S. Air Force Fleet

Palladyne AI included in annual reconstitution of the Russell U.S. Indexes capturing 4,000 largest U.S. stocks for 2025
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.palladyneai.com%2F&amp;esheet=54262364&amp;newsitemid=20250602973600&amp;lan=en-US&amp;anchor=Palladyne+AI+Corp&amp;index=1&amp;md5=e4e79a7c27f7d29dbdcb80a7a8a87be9">Palladyne AI Corp</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDYN#NASDAQ">PDYN</a>) ("Palladyne AI"), a developer of artificial intelligence software for robotic platforms in the defense and commercial sectors, today announced that it has been added as a member of the broad-market Russell 3000&#xAE; Index, effective after the U.S. market opens on June 30, 2025, as part of the 2025 Russell indexes reconstitution.
The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest US stocks as of April 30, 2025, ranking them by total market capitalization. Membership in the Russell 3000Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000&#xAE; Index or small-cap Russell 2000&#xAE; Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

PDYN

Palladyne AI Corp. To Join Russell 3000 And Russell 2000 Index, Effective After The U.S. Market Opens On June 30, 2025

TD SYNNEX Appoints Kenneth Lamneck As Chair Of Nominating And Corporate Governance Committee

Mizuho analyst Anthony Crowdell maintains Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Outperform and raises the price target from $60 to $67.

Mizuho Maintains Outperform on Nextracker, Raises Price Target to $67

<a href="https://www.globenewswire.com/Tracker?data=xdSkUqkMsHzXmkeMPxPhQH6bn-h7JG8NEb30yHWLcWTBly9NJDanE39FJd_1jbdbRapwl3IF95i3r9C7aa--NBjeMyDEyh-fc2nyq5_UNsA=">Aeries Technology, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>), a leading provider of Global Capability Center (GCC) solutions, today announced a strategic partnership with <a href="https://www.globenewswire.com/Tracker?data=v2IS8QBS8duxDdUdtMPBv8MUCf9n3E8pr6zSZWCeqzd7KyH7IrpofI6kTOSlzbucLbNdXHhnIRRI3qRmcrzc3w==">Fortra</a>, a global cybersecurity software and services provider. This collaboration is aimed at establishing GCCs for Fortra in both India and Mexico, to expand their existing India-based workforce and add a nearshore hub.
Aeries will leverage its expertise to deliver purpose-built solutions through these GCCs, focusing on enhancing core business functions. The GCCs will enable Fortra to further access a skilled and diverse talent pool, ensure cost efficiency, and scale operations, aligning strategically with their business objectives. These facilities will serve as a hub for fostering innovation, optimizing operational efficiency, and accelerating digital transformation initiatives.

Advanced Environmental Recycling Technologies

AERT

Aeries Technology Announces Strategic Partnership With Fortra To Expand Existing India-Based Workforce And Add Nearshore Hub

Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) saw its share price surge over 65% during the pre-market trading session on Monday after the company released ORIGIN <a href="https://www.benzinga.com/general/health-care">Phase 3 trial data</a>.
Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in proteinuria as measured by 24-hour urine protein-to-creatinine ratio (UPCR), with a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p&lt;0.0001) at week 36.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44720573/kidney-disease-focused-vera-therapeutics-concludes-enrollment-in-pivotal-study-targets-2026-commercial-launch" rel="noreferrer noopener">Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch</a>
For other prespecified endpoints, atacicept treatment also demonstrated results that were consistent with or better than those previously observed in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717296/vera-therapeutics-announces-atacicept-achieved-46-proteinuria-reduction-in-origin-phase-3-trial-in" rel="noreferrer noopener">ORIGIN Phase 2b trial</a>.
The safety profile of atacicept in this analysis was favorable and comparable to that of the placebo.
Vera plans to share these results with the FDA in the coming weeks, and full results will be submitted to the American Society of Nephrology Kidney Week.
Vera is poised for potential commercial launch of atacicept in 2026, according to Marshall Fordyce, CEO of Vera Therapeutics.
Vera is currently not sharing estimated Glomerular Filtration Rate (eGFR) results.
The trial continues in a placebo-controlled, blinded manner to evaluate the change in kidney function over two years as measured by eGFR and is expected to be completed in 2027.
Price Action: VERA stock is up 58.9% at $30.33 during the premarket session at the last check on Monday.
You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Vera Therapeutics, which is trading at $18.95 as of publishing time, $100 would buy you 5.28 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> 
If your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/05/45703150/gap-flags-over-100-million-tariff-burden-outside-guidance-near-term-stock-pressure-likely-analyst" target="_blank" rel="noreferrer noopener">GAP Flags Over $100 Million Tariff Burden Outside Guidance, Near-Term Stock Pressure Likely: Analyst</a></li>
</ul>
Image: Shutterstock

Health Care

Movers

Trading Ideas

VERA

Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data

Oscar Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) short percent of float has risen 15.08% since its last report. The company recently reported that it has 19.07 million shares sold short, which is 9.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Oscar Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748869272_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Oscar Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Oscar Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Oscar Health's peer group average for short interest as a percentage of float is 2.31%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

OSCR

How Do Investors Really Feel About Oscar Health?

Interparfums's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NYSE">IPAR</a>) short percent of float has fallen 6.09% since its last report. The company recently reported that it has 1.09 million shares sold short, which is 6.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Interparfums Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748869267_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Interparfums has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Interparfums's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Interparfums's peer group average for short interest as a percentage of float is 5.77%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

IPAR

How Is The Market Feeling About Interparfums?

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $68.6, a high estimate of $84.00, and a low estimate of $61.00. A decline of 6.03% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748869261_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Centene is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$61.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$69.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$64.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Centene. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Centene's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Centene's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Centene analyst ratings.</a>
<h2>Discovering Centene: A Closer Look</h2>
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.
<h3>Unraveling the Financial Story of Centene</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 15.38%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Centene's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's ROE excels beyond industry benchmarks, reaching 4.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Centene's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.55% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Centene's debt-to-equity ratio is below the industry average at 0.66, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Centene: 5 Analysts Share Their Views

Guidewire Software's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) short percent of float has risen 16.71% since its last report. The company recently reported that it has 3.85 million shares sold short, which is 4.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Guidewire Software Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748869262_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Guidewire Software has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Guidewire Software's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Guidewire Software's peer group average for short interest as a percentage of float is 2.99%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

GWRE

How Is The Market Feeling About Guidewire Software?

Mizuho analyst Maheep Mandloi maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Outperform and lowers the price target from $7 to $6.

FLNC

Mizuho Maintains Outperform on Fluence Energy, Lowers Price Target to $6

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $130.12, along with a high estimate of $150.00 and a low estimate of $100.00. Marking an increase of 0.22%, the current average surpasses the previous average price target of $129.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1748869252_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Blueprint Medicines's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$130.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blueprint Medicines. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Blueprint Medicines's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Blueprint Medicines's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>Discovering Blueprint Medicines: A Closer Look</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
<h3>Blueprint Medicines: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Blueprint Medicines's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 55.45%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Blueprint Medicines's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Blueprint Medicines's ROE excels beyond industry benchmarks, reaching 0.15%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Blueprint Medicines's ROA stands out, surpassing industry averages. With an impressive ROA of 0.04%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Blueprint Medicines's debt-to-equity ratio stands notably higher than the industry average, reaching 1.36. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPMC

Analyst Expectations For Blueprint Medicines's Future

Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $11.5, a high estimate of $17.00, and a low estimate of $8.00. A decline of 7.26% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748869241_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Canadian Solar is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Canadian Solar. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Canadian Solar compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Canadian Solar's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Canadian Solar's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CSIQ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Canadian Solar analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Canadian Solar</h2>
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
<h3>Canadian Solar: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Canadian Solar's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -9.97%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Canadian Solar's net margin is impressive, surpassing industry averages. With a net margin of -2.84%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Canadian Solar's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.25%, the company showcases efficient use of assets and strong financial health.
Debt Management: Canadian Solar's debt-to-equity ratio stands notably higher than the industry average, reaching 2.34. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSIQ

Canadian Solar Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

During the last three months, 6 analysts shared their evaluations of Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $88.17, a high estimate of $100.00, and a low estimate of $82.00. This upward trend is evident, with the current average reflecting a 3.73% increase from the previous average price target of $85.00.
<img src="https://www.benzinga.com/files/images/story/2025/1748869231_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Fidelity National Info by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Coad</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$84.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Fidelity National Info. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fidelity National Info compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Fidelity National Info's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FIS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fidelity National Info analyst ratings.</a>
<h2>Delving into Fidelity National Info's Background</h2>
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.
<h3>Fidelity National Info's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, Fidelity National Info showcased positive performance, achieving a revenue growth rate of 2.59% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Fidelity National Info's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 3.04%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Fidelity National Info's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.5%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.23%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Fidelity National Info's debt-to-equity ratio is below the industry average at 0.8, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

iCoreConnect

iCoreConnect (ICCT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO